Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from China NT Pharma Group Co., Ltd. ( (HK:1011) ).
China NT Pharma Group has appointed Mr. Kwok Che Chung as an independent non-executive director and chairman of its audit committee, effective 8 May 2026, for a three-year term with annual remuneration of HKD150,000. Kwok brings around 17 years of professional and auditing experience, including roles at KPMG, Canggang Railway, CITIC Capital, Qiming Venture Partners, Arta TechFin and CCT Fortis, and has been confirmed as independent under Hong Kong listing rules.
The appointment follows the resignation of independent non-executive director and former audit committee chairman Mr. Ng Ming Kwan, who is stepping down to focus on personal career development. The board emphasized continuity in governance by welcoming Kwok while expressing gratitude to Ng, signalling an effort to strengthen audit oversight and maintain regulatory compliance amid ongoing board refreshment.
More about China NT Pharma Group Co., Ltd.
China NT Pharma Group Co., Ltd. is a pharmaceutical company listed in Hong Kong, focusing on the development, manufacturing and distribution of healthcare and pharmaceutical products in Mainland China and related markets. The group operates through multiple subsidiaries and maintains a board structure that includes executive, non-executive and independent non-executive directors to meet regulatory and governance standards.
Average Trading Volume: 286,048
Technical Sentiment Signal: Sell
Current Market Cap: HK$607.4M
For a thorough assessment of 1011 stock, go to TipRanks’ Stock Analysis page.